Emgality 120 mg (Galcanezumab SOLUTION) 120 MG

EMGALITY 120 MG is a subcutaneous solution containing galcanezumab, used for migraine prevention. This prescription medication is designed to reduce the frequency of migraine headaches in adults.

Strength

120 MG

Manufacturer / TM Owner

ELI LILLY CANADA INC

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

EMGALITY 120 MG is primarily used for migraine prevention. It is a calcitonin gene-related peptide (CGRP) antagonist, which may help in reducing the number of migraine days experienced by adults. People often ask, 'What is EMGALITY used for?' and the answer is that it is specifically indicated for the preventive treatment of migraines.

Side Effects

Common effects of EMGALITY 120 MG may include injection site reactions, such as redness, pain, or swelling. Some users might experience constipation, upper respiratory infection, or fatigue. These effects vary among individuals and are not exhaustive.

Precautions & Warnings

EMGALITY 120 MG should be used with caution in individuals with a history of hypersensitivity to galcanezumab or any of its components. It is important to follow the advice of a healthcare provider regarding its use, especially for those with other medical conditions.

Avoid Interactions

EMGALITY 120 MG may interact with other medications, including those that affect the immune system or blood pressure. It is advisable to inform a healthcare provider about all current medications before starting EMGALITY. Alcohol and certain supplements might also influence its effects.

Frequently Asked Questions

EMGALITY 120 MG is used for the preventive treatment of migraines in adults.

EMGALITY 120 MG is administered via subcutaneous injection, typically self-administered or administered by a healthcare provider.

Common side effects may include injection site reactions, constipation, upper respiratory infection, and fatigue.

EMGALITY 120 MG is specifically indicated for migraine prevention and not for other types of headaches.

The long-term safety of EMGALITY 120 MG should be discussed with a healthcare provider, as individual responses may vary.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.